Express Scripts 2020 Update 2020 Drug Trend Report: specialty, rare & orphan, and cell & gene therapy management front and
read full article ›Do you know what employers are hearing, what they are looking for from payers, and how that will impact access
read full article ›An interesting look at the sources of copay assistance for privately insured patients (it’s not just manufacturers!). Also cited, nearly
read full article ›Manufacturers think CMS bars them from helping Medicare patients afford their medicines. This is incorrect. There are solutions which can help mitigate patient affordability challenges in Medicare. Join Real Endpoints webinar to understand the role patient support services can play in ensuring affordable access for Medicare beneficiaries.
read full article ›Real Endpoints (RE), a leading boutique life science consultancy focused on market access, today announced it has hired Robert O’Brien as Vice President, Specialty to further expand its abilities to gain access and coverage for its clients’ medical innovations.
read full article ›Ryan Walsh from Real Endpoints has been accepted as one of the prestigious 2020 PharmaVOICE 100 recipients, which recognizes the most inspiring people in the life-sciences industry as leaders in research and development, marketing, technology, creativity, strategy, medicine, etc., positively impacting their peers, colleagues, companies, and communities, as well as the industry at large through their actions.
read full article ›Expert perspectives on reimbursement for high-cost therapies, both chronic and curative, were discussd at the recent Biotechnology Innovation Organization virtual international convention. The panel discussion, moderated by Real Endpoints CEO Jeff Berkowitz, focused on pharmacy benefit manager and payer concerns with affordability, the role of patient advocacy, value-based purchasing, and ICER value assessments
read full article ›Insurers have been playing a beneficial role in the pandemic crises by expanding access to, and cutting patient costs of, Covid-related diagnosis and treatment. How might insurer’s apply the COVID-19 cost-share initiatives to other population-wide problems?
read full article ›Pharmacy workers are the unsung heroes of the COVID-19 crisis, and they are becoming much more important to the pharmaceutical industry, considering that retail pharmacies have drastically lowered the cost of healthcare by making vaccines available at virtually no cost.
read full article ›The reimbursement of emerging durable and potentially curative cell and gene therapies challenge U.S. payers due to their high upfront costs. In addition, the lack of long-term clinical durability data amplifies uncertainties which complicate payer coverage and reimbursement determinations. These cell and gene therapy characteristics could negatively impact patient access and ultimately, future developer innovation. The Financing and Reimbursement of Cures in the U.S. (FoCUS) project was launched in 2016 by MIT with the objective of elucidating the challenges and financial impact created by durable/potentially curative therapies and providing implementable models to manage the financial impact on the U.S. healthcare system.
read full article ›